Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Recruiting now

Conditions studied: Cancer

In brief

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

Key facts

Study ID

NCT02253251

Run by

MiraKind

People needed

15000

Starts

2014-09-01

Expected to finish

2035-09-01

Last updated by the study team

2025-01-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Personal or family history of cancer
• Personal history of endometriosis, or autoimmunity

You may not qualify if…

• Younger than 18
• Non-english speaking and unable to understand and sign the consent

Where it is running

• MiraKind — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.